Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Satofumi, Iida"'
Autor:
Hsi-Hsien Chen, Masaichi Abe, I-Ting Wang, Mizuki Fukazawa-Shinotsuka, Ming-Che Liu, Tomohisa Saito, Kimio Terao, Satofumi Iida
Publikováno v:
Drug Research. 72:23-33
Background Maxacalcitol was approved in Taiwan in 2018 as the first active vitamin D3 injection for secondary hyperparathyroidism (SHPT) in patients on maintenance hemodialysis. However, no data from any clinical study with maxacalcitol in Taiwanese
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51ee8a71fe93fc2b9d8a058ab4106fe3
https://doi.org/10.1055/a-1581-7609
https://doi.org/10.1055/a-1581-7609
Autor:
Akihisa Kaneko, Chihiro Endo-Tsukude, Motohiro Kato, Shino Kuramoto, Masaki Ishigai, Akinobu Hamada, Satofumi Iida
Publikováno v:
Drug Metabolism and Pharmacokinetics. 34:325-333
By using the Relative Factor (RF) method-a method that can simply assess cytochrome P450 (CYP) induction risk based on a maximum induction effect model-we evaluated the risk of CYP2C9 induction and examined its relationship with risk of CYP3A4 induct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc51075349ee3ab7655ad61350d87287
https://doi.org/10.1016/j.dmpk.2019.07.002
https://doi.org/10.1016/j.dmpk.2019.07.002
Autor:
Ghassan K. Abou-Alfa, Takehiko Kawanishi, Norihisa Ohishi, Mikiko Nakamura, Chao Xu, Ya-Chi Chen, Ruey-min Lee, Satofumi Iida, Toshihiko Ohtomo, Cheikh Diack
Publikováno v:
British Journal of Clinical Pharmacology. 84:944-951
Aims Codrituzumab (GC33) is a recombinant, humanized mAb that binds to glypican-3 (GPC3), an oncofetal protein highly expressed in hepatocellular carcinoma (HCC). This investigation aimed to identify clinically relevant factors that may affect the ov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a63d9fac220809ff306179b3fa5845a1
https://doi.org/10.1111/bcp.13530
https://doi.org/10.1111/bcp.13530
Autor:
Dietmar Schwab, Satofumi Iida, Agnès Portron, Sachiya Ikeda, Nahoko Kasahara-Ito, Tomohisa Saito, Yasuki Takano
Publikováno v:
Drug research. 69(6)
Purpose Tofogliflozin is an orally available selective inhibitor of sodium-glucose co-transporter 2 for treatment of type 2 diabetes mellitus (T2DM). Two studies were conducted to evaluate the effect of renal impairment on pharmacokinetics and pharma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3db99e738d172cb6fc05bfeed04e874d
https://pubmed.ncbi.nlm.nih.gov/30103216
https://pubmed.ncbi.nlm.nih.gov/30103216
Autor:
Koichiro Yoneyama, Christophe Schmitt, Naoki Kotani, Takehiko Kawanishi, Gallia G. Levy, Ryu Kasai, Satofumi Iida, Midori Shima
Publikováno v:
Clinical Pharmacokinetics
Background Emicizumab (ACE910) is a bispecific antibody mimicking the cofactor function of activated coagulation factor VIII. In phase I–I/II studies, emicizumab reduced the bleeding frequency in patients with severe hemophilia A, regardless of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50b97d57397273c2950611498ff5a73e
https://pubmed.ncbi.nlm.nih.gov/29214439
https://pubmed.ncbi.nlm.nih.gov/29214439
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Ibandronate is a drug widely used outside Japan for the treatment of osteoporosis. It is available in formulations for intermittent intravenous (i.v.) administration and for intermittent (once monthly) oral administration. Ibandronate was recently ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b1fd007e97c6ba5f8946ea31f137cea
https://doi.org/10.1007/s13318-014-0242-5
https://doi.org/10.1007/s13318-014-0242-5
Autor:
Mikiko, Nakamura, Chao, Xu, Cheikh, Diack, Norihisa, Ohishi, Ruey-Min, Lee, Satofumi, Iida, Takehiko, Kawanishi, Toshihiko, Ohtomo, Ghassan K, Abou-Alfa, Ya-Chi, Chen
Publikováno v:
British journal of clinical pharmacology. 84(5)
AIMS: Codrituzumab (GC33) is a recombinant, humanized mAb that binds to glypican‐3 (GPC3), an oncofetal protein highly expressed in hepatocellular carcinoma (HCC). This investigation aimed to identify clinically relevant factors that may affect the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::843124b866db4624a417477c60696099
https://pubmed.ncbi.nlm.nih.gov/29381229
https://pubmed.ncbi.nlm.nih.gov/29381229
Publikováno v:
Journal of clinical pharmacology. 57(12)
Nemolizumab is a humanized anti-interleukin-31 receptor A monoclonal antibody for treating atopic dermatitis, and it especially improves pruritus. The objective of the simulation study was to optimize the dose regimen using a flat dose. The serum nem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93f3af18c61afd17e780445f7d4afa37
https://pubmed.ncbi.nlm.nih.gov/28703903
https://pubmed.ncbi.nlm.nih.gov/28703903
Autor:
Koji Chiba, Yuto Kyosaka, Takashi Fukushima, Koichiro Yoneyama, Hiroyuki Yoshitsugu, Satofumi Iida, Masaki Hiraoka, Takahiko Tanigawa
Publikováno v:
The Journal of Clinical Pharmacology. 54:483-494
Ethnic evaluation of the pharmacokinetics and safety of new drugs is required in Japan before implementing bridging or joining global studies. As therapeutic monoclonal antibodies (mAbs) show limited ethnic differences, their pharmacokinetics and saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7a203258a6f1f7484c77d5e3ae0cb8e
https://doi.org/10.1002/jcph.231
https://doi.org/10.1002/jcph.231
Publikováno v:
Journal of Pharmacy and Pharmacology. 65:1168-1178
Objectives TP300 is a novel topoisomerase I inhibitor with neutropenia as a significant toxicity. We developed and evaluated a pharmacokinetic–pharmacodynamic (PK-PD) model, using data from Phase I and II trials to predict neutrophil decrease in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62d91ac60ac57bc575901265d0a573f2
https://doi.org/10.1111/jphp.12065
https://doi.org/10.1111/jphp.12065